Czech nanofiber SME applying electrospinning and surface nanostructuring to packaging, dental implants, and biosensing applications.
Nanopharma is a Czech SME specializing in nanofiber and nanostructure technologies, with electrospinning as their core manufacturing capability. They develop functional nanomaterials for diverse applications — from photonic metal oxide nanostructures for biomedical sensing to nanostructured surface treatments for dental implants and advanced packaging materials incorporating Metal Organic Frameworks. Their strength lies in translating nanofiber production expertise into application-specific solutions across health, materials science, and conservation sectors.
Electrospinning appears as a core technology in both CanBioSe (1D metal oxide nanostructures) and NanoSurf (dental implant surfaces), and nanofiber expertise underpins their NEMOSINE packaging work.
NanoSurf focuses on LIPSS nanopatterning and sol-gel surface treatments for implants, while CanBioSe uses ALD for photonic nanostructure fabrication.
NEMOSINE (EUR 517,875 — 97% of their total funding) developed innovative high-barrier packaging with MOF-based gas detection for cultural heritage preservation.
CanBioSe targeted cancer cell detection via optical methods on 1D metal oxides; NanoSurf addressed osseointegration improvement for dental implants using Zr-Ti alloy surface engineering.
All three H2020 projects launched in 2018, making temporal evolution difficult to assess — these represent concurrent rather than sequential interests. However, the project portfolio reveals a deliberate strategy of applying one core technology (electrospinning/nanostructuring) across multiple domains simultaneously: biomedical sensing, dental surgery, and cultural heritage conservation. Their heaviest investment by far was in packaging and conservation (NEMOSINE), suggesting this may be their most commercially mature application area.
Nanopharma appears to be expanding from pure nanomaterial R&D toward application-ready products in packaging and biomedical surfaces, suggesting readiness for closer-to-market collaborations.
Nanopharma operates exclusively as a participant, never coordinating — consistent with a specialist SME that contributes specific manufacturing or material expertise to larger consortia. With 40 unique partners across just 3 projects and 15 countries, they engage in broad, internationally diverse consortia rather than tight repeat-partner clusters. This profile suggests they are sought out for their specific nanofiber capabilities rather than building long-term bilateral research relationships.
Despite only 3 projects, Nanopharma has collaborated with 40 distinct partners across 15 countries, indicating participation in large international consortia. Their network is geographically broad across Europe with no obvious single-country concentration.
Nanopharma's distinguishing feature is their ability to apply electrospinning and nanostructuring across wildly different domains — from cancer detection to dental implants to heritage conservation packaging. Few SMEs offer this breadth of nanomaterial application expertise. For consortium builders, they bring production-oriented nanofiber know-how that bridges the gap between laboratory nanoscience and functional prototypes.
